Packaging

Valois Pharma Makes Organization Changes To Further Ensure Future Innovations

Monday 10. March 2008 - On February 25, 2008, Valois Pharma, world leader in spray and aerosol drug delivery systems, appointed Pascal Bruna as Associate Director Innovation. Bruna will be in charge of implementing the innovation strategy with a focus on exploring and developing new technology platforms.

This new organizational structure is part of the strategy that has been deployed by Valois Pharma since its creation. It is aimed at constant reinforcement of the organization and its teams to ensure that they are ever more focused on innovation. “We are determined to underscore our commitment to innovation even more strongly by creating a specific Research & Development team tasked with driving an innovation dynamic.” said Salim Haffar, President.

Over the last three years, Valois Pharma has made major investments in order to grow its capacity to innovate, building its new R&D center in Le Vaudreuil (France), strengthening its R&D-dedicated teams (110 people), and devoting a constantly expanding budget to new products, a budget now equal to approximately 7% of its annual sales revenue.

The ongoing modernization of its production resources (molds, assembly lines, automated on-line inspections, etc.) and the design and implementation of new processes such as I.M.A.T. (In-Mold Assembly Technology) that enable extremely precise assembly inside the mold on a single machine, ensure that Valois Pharma stays one step ahead.

Haffar added, “This innovation-focused approach is being rolled out alongside scientific and marketing studies driven by a concern to respond as effectively as possible to the requirements of customers and the expectations of patients. In addition, it will allow our team to track the trends in the global pharmaceutical market as closely as possible.”

This strategy has borne fruit insofar as Valois Pharma has consolidated its position as world leader for spray pumps and aerosol metering valves for pressurized inhalers.

In addition, Valois Pharma has continued to protect its inventions by regularly filing several patents each month, building what is today a portfolio of more than 220 patent families.

Since 2005, Valois Pharma has launched several innovative products including Equadel (the first user-independent spray pump), Freepod (the very latest pump designed specifically for preservative-free products), Prohaler (the new dry powder inhaler) and Landmark (a dose indicator for pressurized inhalers) which won an FEA (European Aerosol Federation) International Aerosol Award in 2007.